Clinical Trial Search

Primary: Number of Samples Collected for the Identification of Biomarkers for Early Evaluation of Risk of Developing Hepatosplenic T-cell Lymphoma (HSTCL)

Primary: Percentage of Subjects With at Least One Adverse Event (AE) During the Duration of This Study CDP870-034 (up to 84 Months) — 94.2 percentage of subjects

Primary: Percentage of Participants With Crohn's Disease Activity Index (CDAI) 70 Response Rate — 52.7; 60.1; 62.7; 47.7 Percentage of Participants — p=0.3393

Primary: Mean Extent of Exposure - Duration in Days — 159.2 days

Primary: Number of Participants With Anal HPV of Any Type, Single Type, and Multiple Types — 41; 16; 25 participants

Primary: Cost of Illness in Participants With Crohn's Disease — 6088.40; 6169.62; 5594.00; 5825.80 Euros

Primary: Number of Participants With Adverse Events (AEs) — 453; 147; 360; 96 participants

Primary: Baseline (Wk 0) Disease Activity Score (DAS28) — 4.54; 6.03 Score

Primary: Percentage of Participants With Active CD at Day 1 — 45.3 percentage of participants

Primary: Percentage of Subjects With at Least One Adverse Event (AE) During the Duration of the Study CDP870-033 (up to 84 Months) — 88.2 percentage of subjects

Primary: Maintenance of Symptomatic Remission, Without Worsening of Any Existing Disease Activity During Study Period — -31.63; -27.57 score on a scale — p=0.469

Primary: Serologic, Genetic and Inflammatory Markers Consistent With Inflammatory Bowel Disease — 11 participants testing positive

Primary: Clinical Response — 9 Participants — p=0.03

Primary: The Efficacy of Infliximab in Pyoderma Gangrenosum in Adult Subjects Who Have Inflammatory Bowel Disease — 1 participants

Primary: Dietary Recalls (Calorific Intake) — 1900.9; 2054.3 kcal

Primary: The Crohn's Disease Activity Index (CDAI)-70 Response Rate at Week 8 in Participants Who Received Placebo, PF-04236921 10 mg and PF-04236921 50 mg — 30.6; 35.0; 49.3…

Primary: Number of Participants With MRI Positivity- Global Assessment Positive — 4; 0 Participants

Primary: Prevalence of Inflammation as Diagnosed by Capsule Endoscopy — 6 participants

Primary: Sustained Relapse-free Remission — 6; 5 Participants

Primary: CDAI Clinical Response -100 at Week 8 — 19; 11 Participants

Primary: Crohn's Disease Activity Index (CDAI) Response (Clinical Response or Remission) at Week 6 — 25.0; 43.3; 48.4 percentage of subjects

Primary: Change From Baseline in the Crohn's Disease Endoscopic Index of Severity (CDEIS) Blinded Score at Week 6 — -4.8 Score on a scale

Primary: Percentage of Participants That Achieved Symptomatic Remission at Week 6 — 40; 46 Participants

Primary: Incidence of Adverse Events — 7; 4; 1; 7 events

Primary: Mucosal Change in VCE (Video Capsule Endoscopy) Mucosal Scores and PGA (Physician Global Assessment) — -0.3; -382.9; -2.7 units on a scale — p=0.631

Primary: Number of Participants With Increase in Infection or Serious Adverse Events (SAEs) Related to Single Dose Administration of Ustekinumab — 0 participants

Primary: Number of Patients in Remission at Week 16 — 3; 14 Participants

Primary: Disease Characteristics of Participants: Disease Duration — 63.0; 112.5; 120.0; 86.0 months

Primary: Remission After 8-week of Treatment — 17; 14 Participants — p=0.526

Primary: Number of Occurrences of Adverse Events at 6 Months According to Adverse Event Term — 11; 5; 5; 3 Events